The	O
merits	O
of	O
vascular	B-Multi-tissue_structure
targeting	O
for	O
gynecologic	O
malignancies	B-Cancer
.	O

Neovascularization	O
is	O
an	O
early	O
and	O
critical	O
step	O
in	O
tumor	B-Cancer
development	O
and	O
progression	O
.	O

Tumor	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
are	O
distinct	O
from	O
their	O
normal	O
counterparts	O
morphologically	O
as	O
well	O
as	O
at	O
a	O
molecular	O
level	O
.	O

Recent	O
studies	O
on	O
factors	O
involved	O
in	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
development	O
have	O
identified	O
new	O
therapeutic	O
targets	O
for	O
inhibiting	O
tumor	B-Cancer
neovascularization	O
and	O
thus	O
tumor	B-Cancer
progression	O
.	O

However	O
,	O
the	O
process	O
of	O
tumor	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessel	I-Multi-tissue_structure
formation	O
is	O
complex	O
,	O
and	O
each	O
tumor	B-Cancer
exhibits	O
unique	O
features	O
in	O
its	O
vasculature	B-Multi-tissue_structure
.	O

An	O
understanding	O
of	O
the	O
relative	O
contribution	O
of	O
various	O
pathways	O
in	O
the	O
development	O
of	O
tumor	B-Multi-tissue_structure
vasculature	I-Multi-tissue_structure
is	O
critical	O
for	O
developing	O
effective	O
and	O
selective	O
therapeutic	O
approaches	O
.	O

Several	O
such	O
agents	O
are	O
currently	O
in	O
clinical	O
trials	O
,	O
and	O
many	O
others	O
are	O
under	O
development	O
.	O

In	O
this	O
review	O
,	O
the	O
mechanisms	O
and	O
factors	O
involved	O
in	O
tumor	B-Multi-tissue_structure
blood	I-Multi-tissue_structure
vessel	I-Multi-tissue_structure
formation	O
are	O
discussed	O
.	O

In	O
addition	O
,	O
selected	O
novel	O
classes	O
of	O
antivascular	B-Multi-tissue_structure
therapies	O
,	O
including	O
those	O
targeting	O
tumor	B-Cell
endothelial	I-Cell
cells	I-Cell
and	O
other	O
components	O
of	O
the	O
tumor	B-Multi-tissue_structure
vasculature	I-Multi-tissue_structure
,	O
are	O
summarized	O
.	O

